Literature DB >> 21659941

Prophylactic antibiotic use after intravitreal injection: effect on endophthalmitis rate.

Shabari S Bhatt1, Kimberly E Stepien, Komal Joshi.   

Abstract

PURPOSE: Endophthalmitis after intravitreal injection is a serious complication. There are limited data to support the use of postinjection antibiotics to prevent endophthalmitis. Current endophthalmitis rates after intravitreal injection in the literature are based on studies where patients routinely received postinjection antibiotics. This study retrospectively compares the rate of endophthalmitis in a cohort of patients receiving postinjection antibiotics with that in a group that does not.
METHODS: A retrospective chart review was performed comparing a 12-month period where patients received postinjection topical antibiotics for several days after intravitreal injection with the next 12-month period where no postinjection topical antibiotics were used. Cases of suspected endophthalmitis after intravitreal injection during this period were identified and reviewed.
RESULTS: The rate of clinically suspected endophthalmitis in the cohort of patients receiving postinjection antibiotics after intravitreal injection and that in the cohort that did not was 0.22% and 0.20%, respectively. One culture-positive case was found overall. The difference between the 2 groups is not statistically significant (P = 0.75).
CONCLUSION: The rate of endophthalmitis after intravitreal injections administered in a clinical practice setting when aseptic technique is used is similar with or without the use of postinjection antibiotics.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21659941      PMCID: PMC4459136          DOI: 10.1097/IAE.0b013e31820f4b4f

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  25 in total

1.  Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy.

Authors:  Luiz H Lima; Sandrine A Zweifel; Michael Engelbert; John A Sorenson; Jason S Slakter; Michael J Cooney; James M Klancnik; Lawrence A Yannuzzi; K Bailey Freund
Journal:  Retina       Date:  2009-10       Impact factor: 4.256

2.  Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitis.

Authors:  M G Speaker; F A Milch; M K Shah; W Eisner; B N Kreiswirth
Journal:  Ophthalmology       Date:  1991-05       Impact factor: 12.079

3.  Antibiotic susceptibility patterns of ocular bacterial flora in patients undergoing intravitreal injections.

Authors:  Jason M Moss; Steven R Sanislo; Christopher N Ta
Journal:  Ophthalmology       Date:  2010-06-18       Impact factor: 12.079

4.  Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous.

Authors:  Seenu M Hariprasad; Kevin J Blinder; Gaurav K Shah; Rajendra S Apte; Brett Rosenblatt; Nancy M Holekamp; Matthew A Thomas; William F Mieler; Jingduan Chi; Randall A Prince
Journal:  Arch Ophthalmol       Date:  2005-01

5.  Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials.

Authors:  Abdhish R Bhavsar; Joseph M Googe; Cynthia R Stockdale; Neil M Bressler; Alexander J Brucker; Michael J Elman; Adam R Glassman
Journal:  Arch Ophthalmol       Date:  2009-12

6.  Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch.

Authors:  Kenji Yamashiro; Akitaka Tsujikawa; Kazuaki Miyamoto; Hideasu Oh; Atsushi Otani; Hiroshi Tamuara; Sotaro Ooto; Manabu Sasahara; Daisuke Iwama; Nagahisa Yoshimura
Journal:  Retina       Date:  2010-03       Impact factor: 4.256

7.  A case of sterile endophthalmitis after repeated intravitreal bevacizumab injection.

Authors:  N Melda Yenerel; Umut A Dinc; Ebru Gorgun
Journal:  J Ocul Pharmacol Ther       Date:  2008-06       Impact factor: 2.671

8.  Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin).

Authors:  M Georgopoulos; K Polak; F Prager; C Prünte; U Schmidt-Erfurth
Journal:  Br J Ophthalmol       Date:  2008-11-25       Impact factor: 4.638

9.  Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting.

Authors:  Suman Pilli; Athanasios Kotsolis; Richard F Spaide; Jason Slakter; K Bailey Freund; John Sorenson; James Klancnik; Michael Cooney
Journal:  Am J Ophthalmol       Date:  2008-03-10       Impact factor: 5.258

10.  Severe intraocular inflammation after intravitreal injection of bevacizumab.

Authors:  Tatsuhiko Sato; Kazuyuki Emi; Toshihide Ikeda; Hajime Bando; Shigeru Sato; Shin-ichi Morita; Tomohito Oyagi; Kosaku Sawada
Journal:  Ophthalmology       Date:  2010-01-19       Impact factor: 12.079

View more
  28 in total

1.  Real-World Trends in Intravitreal Injection Practices among American Retina Specialists.

Authors:  Rahul Chaturvedi; Kendall W Wannamaker; Paul J Riviere; Arshad M Khanani; Charles C Wykoff; Daniel L Chao
Journal:  Ophthalmol Retina       Date:  2019-04-04

2.  Antibiotic prophylaxis for preventing endophthalmitis after intravitreal injection: a systematic review.

Authors:  Francesca Menchini; Giacomo Toneatto; Alba Miele; Simone Donati; Paolo Lanzetta; Gianni Virgili
Journal:  Eye (Lond)       Date:  2018-06-11       Impact factor: 3.775

3.  [Bacterial contamination of needles after intravitreal injection in Paraguay].

Authors:  J C Gines; M M Nentwich; A H Peggy Bedoya; P Cibils; A Esteche; F Laspina; M Samudio; N Fariña; H M de Kaspar
Journal:  Ophthalmologe       Date:  2012-08       Impact factor: 1.059

Review 4.  Prevention and treatment of injection-related endophthalmitis.

Authors:  Charles Q Yu; Christopher N Ta
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-05-08       Impact factor: 3.117

5.  Effects of moxifloxacin exposure on the conjunctival flora and antibiotic resistance profile following repeated intravitreal injections.

Authors:  Mustafa Ataş; Burhan Başkan; Ayşe Ozköse; Fatma Mutlu Sarıgüzel; Süleyman Demircan; Emine Pangal
Journal:  Int J Ophthalmol       Date:  2014-10-18       Impact factor: 1.779

6.  The effect of prophylactic topical antibiotics on bacterial resistance patterns in endophthalmitis following intravitreal injection.

Authors:  Philip Storey; Michael Dollin; Nadim Rayess; John Pitcher; Sahitya Reddy; James Vander; Jason Hsu; Sunir Garg
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-05-05       Impact factor: 3.117

7.  Safety and complications of intravitreal injections performed in an Asian population in Singapore.

Authors:  Yanping Xu; Colin S Tan
Journal:  Int Ophthalmol       Date:  2016-05-28       Impact factor: 2.031

8.  Minimizing the endophthalmitis rate following intravitreal injections using 0.25% povidone-iodine irrigation and surgical mask.

Authors:  Hiroyuki Shimada; Takayuki Hattori; Ryusaburo Mori; Hiroyuki Nakashizuka; Kyoko Fujita; Mitsuko Yuzawa
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-02-07       Impact factor: 3.117

9.  Culture-Proven Endophthalmitis After Intravitreal Injection: A 10-Year Analysis.

Authors:  Joseph M Simonett; Austin Igelman; Stanford C Taylor; J Peter Campbell; Thomas S Hwang; Phoebe Lin; Andreas K Lauer; Christina J Flaxel
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2019-01-01       Impact factor: 1.300

10.  Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes.

Authors:  D A M Lyall; A Tey; B Foot; S T D Roxburgh; M Virdi; C Robertson; C J MacEwen
Journal:  Eye (Lond)       Date:  2012-10-12       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.